Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine

G Juhasz1, T Zsombok, B Jakab

  • 1Laboratory of Neurochemistry and Experimental Medicine, and Department of Vascular Neurology, Faculty of Medicine, Semmelweis University, National Institute of Psychiatry and Neurology, Budapest, Hungary.

Cephalalgia : an International Journal of Headache
|February 4, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hippocampal recording with a soft microelectrode array in a cranial window imaging scheme: a validation study.

Scientific reports·2024
Same author

<i>Mirage de tuberculose</i> in the 21<sup>st</sup> century.

Public health action·2024
Same author

Electrophysiological and behavioral properties of 4-aminopyridine-induced epileptic activity in mice.

Biologia futura·2021
Same author

Corrigendum to 'Associations between Facets and Aspects of Big Five Personality and Affective Disorders: Systematic Review and Best Evidence Synthesis' [Journal of Affective Disorders Volume 288 (2021), pages 175-188].

Journal of affective disorders·2021
Same author

Application of a flexible polymer microECoG array to map functional coherence in schizophrenia model.

MethodsX·2020
Same author

Big Five personality facets explaining variance in anxiety and depressive symptoms in a community sample.

Journal of affective disorders·2020

Sumatriptan treatment significantly reduced plasma calcitonin gene-related peptide (CGRP) levels in migraineurs who experienced headache relief. This decrease in CGRP correlates with reduced headache intensity, predicting treatment effectiveness.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Calcitonin gene-related peptide (CGRP) is implicated in migraine pathophysiology.
  • Triptans are a class of drugs used to treat migraine attacks.
  • Understanding the mechanism of triptan action is crucial for migraine management.

Purpose of the Study:

  • To investigate the relationship between sumatriptan administration, plasma CGRP levels, and headache intensity during a migraine attack.
  • To determine if changes in plasma CGRP predict the effectiveness of sumatriptan treatment for migraines.

Main Methods:

  • Nineteen female migraineurs were studied during nitroglycerin-induced migraine attacks.
  • Sumatriptan nasal spray was administered 120 minutes after migraine onset.

Related Experiment Videos

  • Plasma CGRP concentrations and headache intensity were measured immediately before and 60 minutes after sumatriptan administration.

    • Main Results:

    • A significant decrease in plasma CGRP concentration was observed in patients whose headache intensity improved considerably after sumatriptan treatment (P<0.05).
    • Plasma CGRP levels did not change in patients who did not experience headache improvement.
    • Plasma CGRP concentrations showed a significant positive correlation with headache scores at both 60 and 120 minutes post-sumatriptan administration (P<0.05).

    Conclusions:

    • Plasma CGRP concentration decreases in parallel with headache intensity during sumatriptan treatment.
    • The reduction in CGRP levels following sumatriptan administration predicts the drug's therapeutic effectiveness.
    • These findings support the hypothesis that a primary mechanism of triptan action involves the reduction of CGRP release.